BioPharmSignal logoBioPharmSignal

Biotech News

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MediciNova (MNOV)MediciNovaCompany update

LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the target enrollment of 200 patients has been achieved

Related news

MNOVMediciNova2026-09-24 10:00 EST

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

MNOVMediciNova2026-09-28 10:00 EST

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

ANNXAnnexon, Inc.2026-08-06 12:00 EST

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

TSHATaysha Gene Therapies2026-10-01 12:00 EST

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

ANNXAnnexon, Inc.2026-09-24 12:00 EST

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

XENEXenon2026-09-17 20:01 EST

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

TEVATeva Pharmaceutical Industries2026-08-31 20:07 EST

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

XERSXeris Pharmaceuticals2026-08-26 11:30 EST

Xeris Announces Details for XP-8121 Program Overview Webinar

ANVSAnnovis Bio2026-07-07 11:00 EST

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

View all latest news

MediciNova

MediciNova is a biotechnology company with programs in inflammation, fibrosis, and neurological disease. Its story is built around repurposing and selective development rather than broad commercial scale.

Recent company news

MNOVMediciNova2026-09-28 10:00 EST

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MNOVMediciNova2026-09-24 10:00 EST

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

MNOVMediciNova2026-09-08 10:00 EST

MediciNova to Participate in Two Investor Conferences in September

MNOVMediciNova2026-07-15 12:00 EST

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MNOVMediciNova2026-06-30 12:00 EST

MediciNova CEO Provides Shareholder Update

Stock data

Close
1.63 USD
Market cap
65.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States